Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study

Perez-Ruiz, 2002, Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output, Arthritis Rheum, 47, 610, 10.1002/art.10792 Robinson, 2012, Systematic review of the prevalence of gout and hyperuricaemia in Australia, Intern Med J, 42, 997, 10.1111/j.1445-5994.2012.02794.x Zhu, 2011, Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008, Arthritis Rheum, 63, 3136, 10.1002/art.30520 Keech, 2007, Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, Lancet, 370, 1687, 10.1016/S0140-6736(07)61607-9 2010, Effects of medical therapies on retinopathy progression in type 2 diabetes, N Engl J Med, 363, 233, 10.1056/NEJMoa1001288 Takahashi, 2007, Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH, Horm Metab Res, 39, 511, 10.1055/s-2007-982517 Hepburn, 2003, Long-term remission from gout associated with fenofibrate therapy, Clin Rheumatol, 22, 73, 10.1007/s10067-002-0658-1 Khanna, 2012, 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia, Arthritis Care Res, 64, 1431, 10.1002/acr.21772 Richette, 2017, 2016 updated EULAR evidence-based recommendations for the management of gout, Ann Rheum Dis, 76, 29, 10.1136/annrheumdis-2016-209707 2004, The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481], Cardiovasc Diabetol, 3, 9, 10.1186/1475-2840-3-9 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 Bhole, 2010, Epidemiology of gout in women: fifty-two-year followup of a prospective cohort, Arthritis Rheum, 62, 1069, 10.1002/art.27338 2009, WHO-drug reference list (WHO-DRL), 193 Chhana, 2015, Factors influencing the crystallization of monosodium urate: a systematic literature review, BMC Musculoskelet Disord, 16, 296, 10.1186/s12891-015-0762-4 Bardin, 2015, Hyperuricemia starts at 360 micromoles (6 mg/dL), Joint Bone Spine, 82, 141, 10.1016/j.jbspin.2015.01.002 Scott, 2011, Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial, Cardiovasc Diabetol, 10, 102, 10.1186/1475-2840-10-102 Hjortnaes, 2007, Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome, J Rheumatol, 34, 1882 Choi, 2008, Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels—the Third National Health and Nutrition Examination Survey, Rheumatology, 47, 713, 10.1093/rheumatology/ken066 Chino, 2014, SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria, Biopharm Drug Dispos, 35, 391, 10.1002/bdd.1909 Ichida, 2012, Decreased extra-renal urate excretion is a common cause of hyperuricemia, Nat Commun, 3, 764, 10.1038/ncomms1756 Choi, 2008, Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study, BMJ, 336, 309, 10.1136/bmj.39449.819271.BE Seth, 2014, Allopurinol for chronic gout, Cochrane Database Syst Rev, 10 Uetake, 2010, Effect of fenofibrate on uric acid metabolism and urate transporter 1, Intern Med, 49, 89, 10.2169/internalmedicine.49.2597 Nakanishi, 2013, Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate, Nephrol Dial Transplant, 28, 603, 10.1093/ndt/gfs574 Derosa, 2015, Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials, Pharmacol Res, 102, 63, 10.1016/j.phrs.2015.09.012 Feher, 2003, Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout, Rheumatology, 42, 321, 10.1093/rheumatology/keg103 Ansquer, 2008, Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people, Am J Kidney Dis, 51, 904, 10.1053/j.ajkd.2008.01.014 Bastow, 1988, Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial, Metabolism, 37, 217, 10.1016/0026-0495(88)90098-4 Sasaki, 2002, Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study, Clin Ther, 24, 1614, 10.1016/S0149-2918(02)80064-9 Playford, 2002, Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus, Am J Cardiol, 90, 1254, 10.1016/S0002-9149(02)02847-3 Kazumi, 2003, Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study, Curr Ther Res Clin Exp, 64, 434, 10.1016/S0011-393X(03)00127-9 Lee, 2006, Effect of fenofibrate in combination with urate lowering agents in patients with gout, Korean J Intern Med, 21, 89, 10.3904/kjim.2006.21.2.89 Miao, 2011, Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial, Hypertension, 58, 2, 10.1161/HYPERTENSIONAHA.111.171488 Yamamoto, 2001, Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol, J Rheumatol, 28, 2294 Reinders, 2009, Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol, Ann Rheum Dis, 68, 51, 10.1136/ard.2007.083071 Neogi, 2015, 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 74, 1789, 10.1136/annrheumdis-2015-208237